arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ABVC BIOPHARMA, INC.

ABVC
$1.02 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

ABVC BIOPHARMA, INC. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $20.5M
Dividend Yield
Revenue Growth -41.9%
Op. Margin None
ROIC -64.5%
FCF / Share $-0.15
Trailing P/E
Price / Book 2.3x
FCF Yield
Debt / Equity 0.07
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$296.00K
↓ -41.9%
Net Income Profit after all expenses
$-7.91M
↓ -61.3%
FCF / Share Free cash flow per share
$-0.15
↑ +4.2%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
12
Financial Health
45
Cash Quality
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 64 quarters